Show simple item record

dc.contributor.authorDavies, MMen_US
dc.contributor.authorMathur, Pen_US
dc.contributor.authorCarnochan, Pen_US
dc.contributor.authorSaini, Sen_US
dc.contributor.authorAllen-Mersh, TGen_US
dc.date.accessioned2018-09-18T14:44:22Z
dc.date.issued2002-01-07en_US
dc.identifier1en_US
dc.identifier.citationBRITISH JOURNAL OF CANCER, 2002, 86 pp. 123 - 129en_US
dc.identifier.issn0007-0920en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2798
dc.identifier.doi10.1038/sj.bjc.6600020en_US
dc.description.abstractOne explanation for the clinical association between tumour vascularity and probability of metastasis is that increased primary tumour vascularity enhances haematogenous dissemination by offering greater opportunity for tumour cell invasion into the circulation (intravasation). We devised an experimental tumour metastasis model that allowed manipulation of primary tumour vascularity with differential exposure of the primary and metastatic tumour site to angiogenic agents. We used this model to assess the effects of local and systemic increases in the level of the angiogenic agent basic fibroblast growth factor on metastasis. BDIX rats with implanted hind limb K12/TR adenocarcinoma tumours received either intratumoural or systemic, basic fibroblast growth factor or saline infusion. Both intratumoural and systemic basic fibroblast growth factor infusion resulted in significant increases in tumour vascularity, blood flow and growth, but not lung metastasis, compared with saline-infused controls. Raised basic fibroblast growth factor levels and increase in primary tumour vascularity did not increase metastasis. The clinical association between tumour vascularity and metastasis is most likely to arise from a metastatic tumour genotype that links increased tumour vascularity with greater metastatic potential.en_US
dc.format.extent123 - 129en_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.titleEffect of manipulation of primary tumour vascularity on metastases in an adenocarcinoma modelen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/sj.bjc.6600020en_US
rioxxterms.licenseref.startdate2002-01-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBRITISH JOURNAL OF CANCERen_US
pubs.notesunique-id: ISI:000174150200023en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.volume86en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorCarnochan, Paulen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record